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• Advance novel, new medical innovations for the diagnosis, 
treatment, prevention and control of human and animal 
disease – To clinical proof of concept.
• Create a culture of multi-disciplinary, multi-organizational 
Institute Objectives
collaboration focused on advancing medical innovations from 
discovery to commercialization.
• Prepare graduate and postdoctoral students for careers in 
development and commercialization of medical innovations.
• ~$16.1 M over five years beginning January 1, 2009
» $8.1M from Kauffman Foundation
» $8.0M match from  KUEA
• Advisory Board makes project funding decisions
• Industry experienced project managers
• Fellowships
Features of the Grant
» 10 graduate students
» 4 postdoctoral students
» 1 additional postdoctoral fellowship through Kauffman national fellows program
• ~$1.6M per year proof of concept funds available to projects 
actively managed by Institute
• Nine industry adjunct instructors
• Seminars, showcases, and networking of innovations
• Market research performed in collaboration with KU Business 
School
Proof of Concept Overview
• $1.6 million annual budget for investment in faculty research
• RFP and ad hoc funding mechanisms
» Projects from both mechanisms meet same criteria and are 
reviewed and approved by Advisory Board
• Funding is milestone driven, focused on assisting project 
teams in advancing projects from one go/no go decision 
point to the next in an overall project plan.
• IAMI staff work with PI and project teams to identify 
commercialization and follow-on funding opportunities
Christopher P. Austin, Director, National Institutes of Health Chemical 
Genomics Center
Steven D. Averbuch, Vice President, Oncology Global Clinical Research, 
Bristol-Myers Squibb Company
Anand C. Burman, Chairman of the Board, Dabur India Limited, New Delhi, 
IAMI Advisory Board
India
David Jenkins, Managing Partner, FatBoy Capital, L.P.
Michael D. Webb, Executive Chairman, Virtify, Inc.
David Vranicar, President, Heartland Bioventures, Kansas Bioscience Authority
Thomas Wiggans, former Chief Executive Officer and Chairman of the Board, 
Peplin, Inc.
Mike Baltezor (Enturia Inc, a Cardinal Health company)
Tony Barnes (Rules Based Medicine)
Mike Beckloff (Beckloff Associates, a Cardinal Health company)
Tom Engler (Eli Lilly & Co.)
IAMI Adjunct Instructors
Bo Fishback (Kauffman Foundation, Orbis Pharmaceuticals Inc.)
Ken Lynn (New Link Genetics)
Matt McClorey (Lawrence Regional Technology Center)
John Neet (J.M. Neet & Associates. Lawrence, KS)
Andrew Parkinson (Xenotech)
• Key differentiator for NCI designation
» Mission to become #1 academic generator of anti-cancer 
agents
» Drug Discovery, Delivery and Development Program (D4)
» NCI Experimental Therapeutics (NExT) Program
• Long-standing formulation contract.
Supporting Translational Research Initiatives
• Key differentiator for Clinical and Translational Science 
Award (CTSA) application
» Grant submitted in October, 2009
» Last chance submission date June 1, 2010
Proof of Concept Criteria
Project objectives, go/no go decision points, and detailed 
project plans are required for funding consideration and 
project funding proposals are required to address:
• Medical innovation novelty (unmet need)
• Potential market size
• Market definition
• Medical innovation maturity
• Utility of proof of concept funding
• Intellectual property position
• Principal investigator credibility
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In the Clinic This Year: 
1)  Nanotax®
2)  SR-13668
3)  Ciclopirox
The IAMI Innovation Fellows Training Program
• The IAMI program is available to KU master’s and doctoral candidates
from the Schools of Business, Pharmacy, Engineering, Medicine, and
other applicable clinical health sciences disciplines.
• Post-doctoral fellowships are available to those who are no more than
five years post-receipt of their PhD or MD in a field related to
pharmacy, engineering, or clinical health sciences.
• A required deliverable for all IAMI Fellows is a comprehensive
Research Commercialization Plan presented orally to the IAMI
Leadership Team that also serves as the fellow selection committee.
This plan includes a written evaluation from academic and relevant
industry advisors.
Ellis Family Seminar Series
• Location alternated between the KU-Lawrence campus 
and the KUMC campus
• Open to the public
• Individuals from regional industry, universities, and 
research institutes will be invited to attend the seminars 
• Captured in video format and transmitted by an interactive 
webinar format to both campuses and other regional 
campuses
» live interactive questions between campuses or 
individual computers
» post lectures (slides or video of speakers) IAMI website 
to be viewed by anyone without additional cost
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